![Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 - Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -](https://onlinelibrary.wiley.com/cms/asset/be8acbe9-0393-49ef-ab35-0db6de161797/apt_4456_f1.gif)
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
![Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders | Pharmacology Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders | Pharmacology](https://www.frontiersin.org/files/Articles/808195/fphar-13-808195-HTML/image_m/fphar-13-808195-g001.jpg)
Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders | Pharmacology
![Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. - Abstract - Europe PMC Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3784550/bin/JCI70837.t2.jpg)
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. - Abstract - Europe PMC
![Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis](https://mma.prnewswire.com/media/428177/TheravanceBiopharmaLogo_Logo.jpg?p=facebook)
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
![Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study - Kuo - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study - Kuo - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/194c97d3-e818-4aa4-9f13-c1ebc41d6ede/apt16344-toc-0001-m.jpg)
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study - Kuo - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
![Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis | Gut Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis | Gut](https://gut.bmj.com/content/gutjnl/66/9/1611/F2.large.jpg)
Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis | Gut
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis | Clinical Research Trial Listing ( Gastroparesis ) ( NCT01718938 )
![Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis - The Lancet Gastroenterology & Hepatology Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis - The Lancet Gastroenterology & Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0fc83fc6-01a9-4010-a9c0-639aaab106bb/gr1_lrg.gif)